Photo by Pharmacy Images on Unsplash
Long Covid Medications Now Covered by German Health Insurance
Starting soon, statutory health insurance providers in Germany will cover the cost of four off-label medications prescribed to treat Long Covid symptoms. Until now, patients with Long Covid had to bear the expenses of these prescription drugs themselves. This development follows a decision by the Gemeinsame Bundesausschuss (G-BA), the federal committee responsible for determining which treatments are reimbursable, marking a significant shift in patient care for those enduring prolonged Covid-19 effects [Source 1][Source 3][Source 6].
Long Covid refers to symptoms continuing or emerging at least four weeks after initial coronavirus infection, with fatigue, exhaustion, cognitive impairments, and pain among the commonly reported issues. The affected population in Germany is estimated at around one million people [Source 4].
Details on the Four Approved Medications
The four drugs approved for reimbursement by the G-BA are originally licensed for other indications but have demonstrated potential benefits for Long Covid patients. These include:
- Agomelatin – an antidepressant shown to alleviate severe fatigue (post-infectious Fatigue Syndrome or ME/CFS) common in Long Covid sufferers.
- Metformin – commonly used for diabetes management, it may help prevent Long Covid in overweight individuals.
- Ivabradin – aimed at treating postural orthostatic tachycardia syndrome (PoTS), a condition associated with Long Covid that causes heart rate irregularities.
- A fourth unnamed medication was also approved but specific details were not fully disclosed in the available sources [Source 1][Source 3][Source 7][Source 8].
These treatments are made available under “Off-Label Use,” meaning they are prescribed for conditions outside their original approval but with professional evaluation indicating therapeutic benefit [Source 7][Source 8]. The G-BA decision awaits expected approval by the Federal Ministry of Health for formal implementation [Source 3].
Implications for Expats and Foreign Residents in Germany
This policy change directly affects expatriates, international students, and foreign workers insured under Germany’s statutory health system. Previously, individuals suffering Long Covid had to cover medication costs out-of-pocket, which could be substantial given the chronic nature of symptoms. Now, with insurance coverage for these off-label medications, the financial burden will reduce significantly when prescribed by a physician [Source 1][Source 4].
Foreign residents should ensure their health insurance status under the statutory scheme and consult their healthcare providers about eligibility for these treatments. Expats relying on private or foreign insurance may need to verify whether their policies cover such off-label uses, as the change specifically impacts statutory health insurers.
This measure does not alter rights or obligations related to Covid vaccination or other preventive care but represents a major advancement in support for Long Covid sufferers. It is recommended that affected individuals discuss their treatment options with their doctors and check prescriptions against the new coverage regulations [Source 4][Source 7].
Background and Next Steps
The decision is based on expert evaluations conducted by a specialized panel under the Federal Institute for Drugs and Medical Devices (BfArM), which examined medical benefits of various substances for Long Covid treatment. Following these expert recommendations, the G-BA acted swiftly to include these medications in the reimbursement list, which involves liability agreements from pharmaceutical companies to cover off-label prescription risks [Source 8].
While no medications are officially licensed specifically for Long Covid yet, this off-label approval is seen as an urgent response to the high demand for effective treatment options. Federal Health Minister Nina Warken highlighted the importance of this step, emphasizing its role in improving care and providing hope to patients [Source 4].
Additional information and patient guidance will likely follow as the Federal Ministry of Health finalizes the legal approval, making the new reimbursement status effective in the near future [Source 3].
For more details, readers can consult the original report in German: Long Covid: Krankenkassen übernehmen bald einzelne Medikamente [Source 1].
